LONDON, Nov 19 (Reuters) - Swiss drugmaker Novartis on Thursday outlined new mid-term sales targets that were at the lower end of the range it had given a year earlier, ahead of its annual investor event in London. Novartis now expects net sales to grow 5% annually at constant currencies from 2026 through 2031. Previously, the company expected sales growth of 5%-6% through 2030.

(Reporting by Bhanvi Satija and Marleen KaesebierEditing by Dave Graham)

Find it fast

Looking for more insights? Explore our other news sections for updates on sustainable finance, companies and financial education